Guardant Health stock hits 52-week high at 64.74 USD

Guardant Health Inc. (GH) stock reached a new 52-week high of $64.74, following robust Q2 2025 financial results that significantly exceeded expectations, with EPS of -$0.44 (vs. -$0.72 anticipated) and revenue of $232.1 million (vs. $211.27 million expected). The company subsequently raised its full-year revenue growth guidance to 24-25% year-over-year from 15-16%, prompting Scotiabank to increase its price target to $60 while maintaining a Sector Outperform rating. This performance reflects strong investor confidence and growth momentum in the healthcare diagnostics sector, though InvestingPro analysis indicates the stock appears slightly overvalued at current levels.

Analysis

Guardant Health (GH) has demonstrated significant operational and market momentum, with its stock reaching a new 52-week high of $64.74, contributing to a 108% year-to-date gain. This surge is fundamentally supported by a strong second-quarter 2025 financial report, where the company substantially beat analyst expectations. Specifically, Guardant posted an EPS of -$0.44, well ahead of the anticipated -$0.72, and revenue of $232.1 million, which surpassed forecasts by 9.86%. Critically, management has materially raised its full-year revenue growth guidance from a 15-16% range to 24-25% year-over-year, signaling strong confidence in its business trajectory. This positive outlook was reinforced by Scotiabank, which increased its price target to $60 while maintaining a Sector Outperform rating. Despite these bullish indicators and a healthy current ratio of 3.71 pointing to strong liquidity, a note of caution is introduced by an external analysis suggesting the stock appears slightly overvalued at its current peak.

Key Decisions for Investors

• Investors should weigh the company's powerful fundamental momentum, underscored by the major earnings beat and significantly upgraded revenue guidance, against valuation risk as the stock trades at a 52-week high.
• Monitor the company's execution against its newly raised 24-25% revenue growth forecast, as meeting this higher bar is now critical for sustaining the stock's current valuation premium.
• While Scotiabank's 'Sector Outperform' rating is positive, its price target of $60 is below the recent high, suggesting potential investors should consider whether near-term upside is already priced in following the stock's 147.78% run-up over the past year.